Back to today’s briefing

Story perspectives

DOJ Probes Genetic Testing Kickbacks Amid Biopharma Settlements

6/18/2025

50 12

Summary

Story summary

The US Department of Justice is investigating genetic testing programs backed by biopharmaceutical firms, focusing on potential drug marketing kickbacks. Companies like QOL Medical and Ultragenyx have already settled for alleged misconduct. Experts stress the importance of keeping clinical decisions distinct from sales tactics to protect patients and navigate legal challenges effectively.

1 of 1

Story summary

The US Department of Justice is investigating genetic testing programs backed by biopharmaceutical firms, focusing on potential drug marketing kickbacks. Companies like QOL Medical and Ultragenyx have already settled for alleged misconduct. Experts stress the importance of keeping clinical decisions distinct from sales tactics to protect patients and navigate legal challenges effectively.